TrialNature communications2024

Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial.

Tina J Hieken et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.